Morphosys and Novartis select second area for antibody co-development
This article was originally published in Scrip
Executive Summary
Morphosys and Novartis have identified a second area in which the two companies will co-develop therapeutic antibodies as part of their $600 million 10-year deal, signed in 2007. It has never been clear exactly what the commercial expectations of that agreement were. However, Morphosys's CEO Dr Simon Moroney told Scrip that although the selection of programmes by Novartis had been "slightly more spread-out" than he would have hoped for, there had been no fixed timeline for selecting programmes for co-development.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.